Electrogram-Guided Myocardial Advanced Phenotyping

Non-ischemic Cardiomyopathy Clinical Trial

— eMAP  

Official title:

Electrogram-Guided Myocardial Advanced Phenotyping (The eMAP Trial)

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

• NCT number: NCT03293381
• Other study ID #: 826102
• Status: Enrolling by invitation
• Start date: November 30, 2018
• Est. completion date: November 30, 2025

Study information

• Verified date: February 2024
• Source: University of Pennsylvania
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Fluoroscopy guided EMB and EAM guided EMB on all patients meeting existing guidelines for biopsy.

Description:

Non-Ischemic Cardiomyopathy (NICM) is a common cause of heart failure (HF) and death. NICM is a heterogeneous entity, and specific etiologies are infrequently identified. In part due to limited disease characterization, specific treatments are lacking for most of the different underlying causes of NICM. Depending on the cohort, 30-70 percent of patients with new-onset NICM develop persistent systolic dysfunction despite guideline-directed medical therapy, and these patients have high rates of subsequent morbidity and resource utilization.

Current guidelines support the use of endomyocardial biopsy (EMB) in patients with both new-onset and persistent cardiomyopathy. However, EMB is underutilized in these populations due to its low diagnostic yield. A combination of sampling error resulting from standard fluoroscopy-guided EMB in disease entities with patchy myocardial involvement and rudimentary tissue phenotyping of the specimens which are obtained contribute to this low diagnostic yield. In recent years, there has been increasing interest in the use of electro-anatomic mapping (EAM) to help identify areas of myocardium with discrete pathology based on abnormalities in intra-cardiac electrogram voltage and morphologies. Therefore, the primary objective of this protocol is to provide definitive evidence that EAM-guided biopsy leads to a superior diagnostic yield compared with conventional fluoroscopy-guided biopsy in patients with new-onset and persistent NICM.

Recruitment information / eligibility

• Status: Enrolling by invitation
• Enrollment: 60
• Est. completion date: November 30, 2025
• Est. primary completion date: November 30, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

1. Age = 18 years

2. New onset NICM as defined by the presence of left ventricular dysfunction (LVEF < 45% by echocardiography and/or MRI), with symptoms or signs of HF (dyspnea, orthopnea, edema, ascites, rales or pulmonary vascular congestion on chest radiography) of less than 3 months in duration.

3. Persistent recent onset NICM as defined by the LVEF and signs/symptoms in #2 above with persistence of the LVEF < 45% despite evidence-based treatment for HF with reduced LVEF for 2 to 6 months.

4. Willingness to provide informed consent

-

Exclusion Criteria:

1. Prior diagnosis of HF or documented LVEF < 45% more than 6 months prior to enrollment.

2. Coronary artery disease, either by history or as determined by coronary angiography demonstrating hemodynamically significant lesions deemed sufficient to potentially contribute to left ventricular dysfunction.

3. Ongoing hemodynamically significant arrhythmias deemed to be an independent cause of HF decompensation

4. Constrictive pericarditis or tamponade

5. Complex congenital heart disease

6. History of malignancy with treatment by anthracyclines or other known cardiotoxic chemotherapeutic agents

7. More than mild aortic or mitral stenosis

8. Intrinsic (prolapse, rheumatic) valve disease with severe mitral, aortic or tricuspid regurgitation

9. Primary hypertrophic cardiomyopathy

10. Untreated thyroid disease

11. Severe nutritional deficiency

12. Severe uncontrolled hypertension

13. Sepsis, active infection (excluding cystitis) or other comorbidity driving the HF decompensation

14. History of cardiac transplantation

15. Acute or chronic severe liver disease as evidenced by any of the following:

encephalopathy, variceal bleeding, INR > 1.5 in the absence of anticoagulation treatment

16. Inability to comply with planned study procedures

-

Related Conditions & MeSH terms

• Cardiomyopathies
• Non-ischemic Cardiomyopathy

Intervention

Device:
• additional biopsies
additional biopsies

Locations

Country	Name	City	State
United States	University of Pennsylvania	Philadelphia	Pennsylvania
United States	Mayo clinic	Rochester	Minnesota

Sponsors (2)

Lead Sponsor	Collaborator
University of Pennsylvania	Biosense Webster, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Fluoroscopy guided EMB and EAM guided EMB on all patients meeting existing guidelines for biopsy.	Additional biopsies	November 2018